Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.41 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL28251997 | 0.88 | CTSK (0.44) | CTSKBTKGAAKCNA3NFKB1 | |
| SCHEMBL14824210 | 0.87 | CTSK (0.53) | CTSKBTKGAAKCNA3NFKB1 | |
| SCHEMBL28539529 | 0.80 | GAA (0.50) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL26873668 | 0.78 | EPHX2 (0.46) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL29045771 | 0.78 | BTK (0.49) | CTSKBTKGAAKCNA3NFKB1 | |
| SCHEMBL17236093 | 0.76 | CTSK (0.49) | CTSKBTKGAAKCNA3NFKB1 | |
| SCHEMBL9078331 | 0.76 | NFKB1 (0.49) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL570801 | 0.74 | GAA (0.54) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL28016881 | 0.74 | CTSK (0.46) | CTSKBTKGAAKCNA3NFKB1 | |
| SCHEMBL571098 | 0.73 | BTK (0.50) | CTSKBTKGAAKCNA3NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4298099-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220281887-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-09-08 | — | — | US | disclosed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | JAK2, JAK1, STAT5A | CTSK 3766/4885BTK 9/4885GAA 2704/4885 |
| US-20220281887-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | JAK2, JAK1, STAT5A | CTSK 3766/4885BTK 9/4885GAA 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.